-
Company Profile
![]()
Zydus Wellness Ltd – Company Profile
Zydus Wellness Ltd (Zydus), a subsidiary of Zydus Lifesciences Ltd, manufactures, distributes and markets health food, nutrition and skincare products. The company's product portfolio comprises sugar substitute sweetener, cholesterol free table spread, nutritional health drink and facial skincare products. Its facial skincare products includes facial scrub, facial peel-off mask, and face wash. The company's sugar free sweetener is made from a protein derivative called Aspartame. Zydus offers these products under various brands, including Complan, Glucon-D, Sugar Free, Nutralite, Everyuth, Nycil,...
Add to Basket -
Company Profile
![]()
Zydus Lifesciences Ltd – Company Profile
Zydus Lifesciences Ltd (Zydus Lifesciences) formerly Cadila Healthcare Ltd is an integrated global healthcare provider. It discovers, develops, manufactures and commercializes various healthcare products. The company’s product portfolio includes active pharmaceutical ingredients (APIs), formulations, wellness and animal health products. Zydus Lifesciences products find application in the treatment of diseases in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others. It conducts research to develop biologics, biosimilars, vaccines and new chemical entities. The...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Aceclidine in Presbyopia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Aceclidine in PresbyopiaDrug Details:Aceclidine (LNZ100) is under development for the treatment of presbyopia. It acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HBI-0201 in Metastatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HBI-0201 in Metastatic CancerDrug Details:HBI-0201 is under development for the treatment of metastatic cancers. The therapeutic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pertuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Pertuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cudetaxestat in Systemic Sclerosis (Scleroderma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cudetaxestat in Systemic Sclerosis (Scleroderma) Drug Details: Cudetaxestat is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sapacitabine in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sapacitabine in Pancreatic Cancer Drug Details: Sapacitabine is under development for the treatment of relapsed/refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Desidustat in Chemotherapy Induced Anemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Desidustat in Chemotherapy Induced Anemia Drug Details: Desidustat (Oxemia) is an erythropoietin-stimulating agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Saroglitazar in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details:Saroglitazar (lipaglyn) is the first Glitazar having...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Saroglitazar in Liver Diseases
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Saroglitazar in Liver DiseasesDrug Details:Saroglitazar (lipaglyn) is the first Glitazar having lipid and glucose lowering effects...
-
Track & Monitor
New![]()
Innovation in pharma: anti-malarial peptides
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s anti-malarial peptides innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience in...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lurbinectedin in Germ Cell Tumors
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lurbinectedin in Germ Cell Tumors Drug Details: Lurbinectedin (Zepzelca) is a synthetic tetrahydropyrrolo [4, 3,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M&A in the Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry...
-
Product Insights
Transmucosal Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transmucosal Drug Delivery Pipeline Market Report Overview A Transmucosal drug delivery device is intended for the localized delivery of medications through a mucous membrane. The transmucosal drug delivery pipeline market research report provides comprehensive information about the transmucosal drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segment ·      Nasal ·      Vaginal ·      Buccal Delivery ·      Rectal Key Territories ·      The US...
-
Sector Analysis
![]()
New Drug Approvals and Their Contract Manufacture – 2023 Edition
Explore actionable market insights from the following data in our ‘New Drug Approvals and Their Contract Manufacture’ report. This report is required reading for - CMO executives who must have a deep understanding of drug approvals and outsourcing to make strategic planning and investment decisions. Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. Private equity investors who need a deeper understanding of the market to...
-
Product Insights
Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dengue Fever Pipeline Drugs Market Report Overview Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style. The dengue fever pipeline...
-
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Report Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The...
-
Product Insights
Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness, and inability to think clearly. The renal...
-
Product Insights
![]()
Net Present Value Model: Asacol
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Asacol Drug Details Mesalamine (Asacol, Asacol...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.